Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna Inc.’s stock fell 3% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...
Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
FiercePharma6h
Moderna shoulders $238M contract manufacturing cancellation charge in Q4
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
Moderna (MRNA) Is About to Report Tomorrow. Here Is What to Expect
Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past ...
Moderna stock down pre-market on mixed 2024 earnings
Moderna reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday.
FiercePharma1d
Moderna trims digital team, lays off employees as chief information officer departs
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
Moderna (MRNA) Q4 2024 Earnings Call Transcript
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
Moderna price target lowered to $25 from $35 at Wolfe Research
Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...